• Hunter Capital RTO 1 extended its non-binding letter of intent with ResoTher Pharma for a planned reverse acquisition transaction.
• The deadline moved to Dec. 31, 2026 from Sept. 30, 2026 to allow time to complete remaining steps.
• Key terms of the proposed deal remain unchanged, aside from the revised timetable.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hunter Capital RTO 1 AB (publ) published the original content used to generate this news brief via Cision (Ref. ID: 202609300845BITN____UKPR__SV_20260930-BIT-7380-0) on September 30, 2026, and is solely responsible for the information contained therein.